who medicines strategy - libdoc.who.int - World Health Organization

WHO MEDICINES STRATEGY 2004-2007 | 148of Essential Medicines). Geneva, World Health Organization, 1998 (WHO Technical Report Series No.882).32World pharmaceutical situation survey 1999. World Health Organization. EDM/DAP.33Quick JD. Editorial. Essential medicines twenty-five years on: closing the access gap. Health Policy andPlanning 2003;18(i):1-3.34Guidelines for drug donations.2 nd ed. Interagency guidelines. Geneva, World Health Organization, 1999(WHO/EDM/PAR/99.2).35Guidelines for price discounts of single-source pharmaceuticals. Geneva, World Health Organization,2003 (WHO/EDM/PAR/2003.3).36How to develop and implement a national drug policy, 2 nd ed. Geneva, World Health Organization,2001.37Quick JD et al (eds). Managing drug supply. 2nd ed. West Hartford, Connecticut, Kumarian Press, 1997.38Kaplan WA, Laing R. Is local production of pharmaceuticals a way to improve pharmaceuticalaccess in developing and transitional countries? Setting a research agenda.. Unpublished document.Boston University School of Public Health (http://dcc2.bumc.bu.edu/richardl/RPM+_Project/local_production.htm).39Operational principles for good pharmaceutical procurement. Interagency guidelines. Geneva, WorldHealth Organization, 1999 (WHO/EDM/PAR/99.5).40Quick JD et al (eds). Part III, Section B, Procurement. In: Managing drug supply. 2nd ed. West Hartford,Connecticut, Kumarian Press, 1997.41Surmounting challenges: procurement of antiretroviral medicines in low- and middle-Income countries.Geneva, World Health Organization, Médecins Sans Frontières and Joint United Nations Programme onHIV/AIDS, 2003.42The impact of implementation of ICH guidelines in non-ICH countries. Report of a WHO Meeting.Geneva, 13-15 September 2001. Geneva, World Health Organization, 2002. Regulatory Support Series,No.9 (WHO/EDM/QSM/2002.3).43Quality assurance of pharmaceuticals - A compendium of guidelines and related materials, Vol 1,Geneva, World Health Organization, 1997. Vol 2. Geneva, World Health Organization, 1999.44WHO Expert Committee on Specifications for Pharmaceutical Preparations, 38 th Report. Geneva, WorldHealth Organization 2004 (Technical Report Series No. 908).45The international pharmacopoeia, 3 rd ed., Vol. 1-5. Geneva, World Health Organization, 2003.46Guidelines for the WHO review of dependence-producing psychoactive substances for internationalcontrol. Geneva, World Health Organization, 2000 (WHO/EDM/QSM/2000.5).47Achieving balance in national opioids control policy: Guidelines for assessment. Geneva, World HealthOrganization, 2000 (WHO/EDM/QSM/2000.4).48Report of the International Narcotics Control Board for 2002. Vienna, United Nations, 2002 (E/INCB/2002/1).49Effective drug regulation: what can countries do? Theme paper for discussion. Geneva, World HealthOrganization, 1999 (WHO/HTP/EDM/Mac (11)99.6).50Annual report 2001 - Essential Drugs and Medicines Policy: Extending the evidence base. Geneva,World Health Organization, 2002.51ibid.52Effective medicines regulation: ensuring safety, efficacy and quality. Geneva, WHO Policy Perspectiveson Medicines, No.7. Geneva, World Health Organization, 2003 (WHO/EDM/2003.2).53Reggi V et al. Prescribing information in 26 countries: a comparative study. European Journal of ClinicalPharmacology, Aug 2003; 59(4):263-70.54Ratanwijitrasin S, Wondemagegnehu E. Effective drug regulation - A multicountry study, and Annex 1:Guide for data collection to assess drug regulatory performance. Geneva, World Health Organization,2002.55Quick JD. Ensuring access to essential medicines in developing countries – A framework for action.Geneva, World Health Organization. Presentation at the 25 th Anniversary of Essential MedicinesSeminar, Geneva, 21 October 2002.56The selection and use of essential medicines. Report of the WHO Expert Committee 2002 (including the